Access Pharmaceuticals (ACCP) Release: MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients 7/23/2009
More...
|
SciClone Pharmaceuticals, Inc. (SCLN) Announces First Patient Enrolled in Phase 2 Clinical Trial Using SCV-07 to Prevent Oral Mucositis 12/22/2008
More...
|
The GI Company Reports Additional Phase II Clinical Data of Intestinal Trefoil Factor (rhITF) Oral Spray for Oral Mucositis 6/30/2008
More...
|
The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study Presented at American Society of Clinical Oncology 6/3/2008
More...
|
CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation; New Data Underscore the Utility of CAPHOSOL in Treating Oral Mucositis 5/22/2008
More...
|
Coserics Announces Company Formation Including Spin-Out of Phase 2 Clinical Asset From Serenex 4/17/2008
More...
|
The GI Company to Present Phase I & II Oral Mucositis Data at MASCC/ISOO Annual Meeting 4/7/2008
More...
|
The GI Company to Present Phase II Oral Mucositis Data at American Society of Clinical Oncology Annual Meeting 3/26/2008
More...
|
ActivBiotics Receives FDA Orphan Drug Designation for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis of Cancer 3/6/2008
More...
|
Cytogen Corporation (CYTO) Release: New Survey of Oral Mucositis Sufferers Reveals Lack of Public Awareness and Information About the Condition 6/1/2007
More...
|
Serenex Announces Issuance of European Patent for Oral Mucositis Product SNX-1012 3/20/2007
More...
|
MGI PHARMA, INC. (MOGN) Announces Publication Of Phase 3 Data For Saforis™ (Glutamine) Powder In UpTec™ For Oral Suspension In Cancer - Primary Endpoint Was Met 1/18/2007
More...
|
Cytogen Corporation (CYTO) Acquires North American Marketing Rights To CAPHOSOL(R) For Treatment Of Both Oral Mucositis And Dry Mouth 10/11/2006
More...
|
Mouthwash, Ice Chips Relieve Oral Chemotherapy Sores 10/2/2006
More...
|
Serenex Announces The Start Of A Phase 2 Clinical Trial Of SNX-1012 For The Treatment Of Chemotherapy-Induced Oral Mucositis 7/12/2006
More...
|
Access Pharmaceuticals (ACCP) Announces Clinical Results Of MuGard(TM) At A Major Supportive Care Conference 6/22/2006
More...
|
CuraGen Corporation (CRGN) Initiates Second Phase II Clinical Trial With Velafermin 5/30/2006
More...
|
RxKinetix, Inc. Completes Its End Of Phase 2 Meeting With The FDA For RK-0202 In Oral Mucositis And Is Moving Into Phase 3 3/1/2006
More...
|
CuraGen Corporation (CRGN) Confirms Failed Phase II Results For Velafermin; Shares Drop 2/21/2006
More...
|
CuraGen Corporation (CRGN) Drug For Oral Mucositis Misses Goal 12/13/2005
More...
|
RxKinetix, Inc. Successfully Concludes Its Phase 2 Trial In Oral Mucositis 10/18/2005
More...
|
CuraGen Corporation (CRGN) To Complete Patient Enrollment In Velafermin Phase II Clinical Trial 9/28/2005
More...
|
CuraGen Corporation (CRGN) Presents New Preclinical Data On Velafermin At The 17th Annual International Symposium On Supportive Care In Cancer 7/1/2005
More...
|
Amgen (AMGN) Release: FDA Approves Kepivance For Severe Oral Mucositis In Cancer Patients Undergoing Bone Marrow Transplant; Pivotal Phase 3 Study Published In This Week's New England Journal Of Medicine 12/16/2004
More...
|
CuraGen Corporation (CRGN) Release: Single Dose Phase I Data On CG53135 For The Prevention Of Oral Mucositis Presented At American Society of Hematology (ASH) 12/6/2004
More...
|
CuraGen Corporation (CRGN) Receives Fast Track Designation For CG53135 12/2/2004
More...
|
GeoPharma, Inc. (GORX) Receives FDA Approval For Mucotrol(TM); Manages Mucositis Caused By Radiation And Chemotherapy Required In Cancer Treatment; Shares Surge 12/1/2004
More...
|
CuraGen Corporation (CRGN) Announces Clinical Progress With CG53135 For Oral Mucositis 10/7/2004
More...
|
MGI Pharma (MOGN) To Acquire Aesgen, Inc. -- Saforis For Oral Mucositis Bolsters MGI's Oncology Supportive Care Franchise; $32 Million In Cash 9/1/2004
More...
|
CuraGen Corporation (CRGN) Presents Advances In Therapeutic Pipeline At American Association For Cancer Research Annual Meeting 3/30/2004
More...
|
Interlink Gives Voice To Aesgen, Inc. Oral Mucositis Drug 3/11/2004
More...
|
CuraGen Corporation (CRGN) Receives Orphan Drug Designation From The FDA For CG53135 In Oral Mucositis Indication 2/25/2004
More...
|
Aesgen, Inc. Release: New Treatment Offers Hope For Cancer Patients 12/15/2003
More...
|